
Abbott Labs (ABT) Stock Forecast & Price Target
Abbott Labs (ABT) Analyst Ratings
Bulls say
Abbott Laboratories is projected to achieve organic sales growth of 6.0-7.0% by 2025, with consensus estimates suggesting an increase to $44.69 billion, reflecting a 6.4% year-over-year growth. The company has demonstrated strong performance across its various segments, with notable growth in its Electrophysiology and Structural Heart portfolios, contributing to double-digit organic growth rates in critical areas such as Diabetes and Rhythm management. Furthermore, Abbott's commitment to dividend increases for over 50 consecutive years, alongside a well-capitalized balance sheet positioned for potential mergers and acquisitions, underscores a robust outlook for the company's financial future.
Bears say
Abbott Laboratories is facing significant challenges due to continued declines in Covid-19 testing revenue, which fell to $69 million in Q3 2025 from $265 million in Q3 2024, prompting the company to adjust its outlook regarding the impact of these sales. Additionally, macroeconomic factors such as inflation and foreign exchange fluctuations, along with increased competition in the continuous glucose monitoring market, are contributing to a negative financial landscape for the company. The overall performance in Q3 2025 revealed a top-line revenue miss, primarily due to weaker-than-expected results in its diagnostics segment and delays in clinical trials, which further hinder Abbott's growth prospects.
This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares